LCZ696 (Sacubitril + Valsartan)

Takaitaccen Bayani:

Sunan API Nuni Ƙayyadaddun bayanai Farashin DMF EU DMF CEP
LCZ696 (Sacubitril + Valsartan) Ciwon zuciya Cikin Gida    


Cikakken Bayani

Tags samfurin

BAYANIN KYAUTA

Bayani

LCZ696 (Sacubitril/Valsartan), ya ƙunshi Valsartan (an ARB) da Sacubitril (AHU377) a cikin 1: 1 molar rabo, shi ne na farko-in-aji, na baka bioavailable, da dual-aiki angiotensin receptor-neprilysin (ARN) hanawa ga hauhawar jini. da gazawar zuciya[1][2][3]. LCZ696 yana inganta cututtukan zuciya na ciwon sukari ta hanyar hana kumburi, damuwa na oxidative da apoptosis.

 

Fage

LCZ696 shine na farko a cikin aji ARNi (angiotensin receptor neprilysin inhibitor) wanda ya ƙunshi nau'ikan anionic na AR valsartan da neprilysin inhibitor prodrug AHU377 (1: 1 rabo) don gazawar zuciya da hauhawar jini.

Masu karɓar angiotensin su ne masu karɓa na G-protein-haɗe-haɗe. Suna yin sulhu da cututtukan zuciya da sauran tasirin angiotensin II wanda shine peptide bioactive na tsarin renin-angiotensin. Neprilysin shine endopeptidase mai tsaka tsaki wanda ke lalata peptides na vasoactive na endogenous kamar peptides na natriuretic. Hanawa neprilysin yana ƙara yawan ƙwayar peptides na natriuretic wanda ya ba da gudummawa ga kariyar zuciya, jijiyoyin jini da na koda. [1]

A cikin berayen Sprague-Dawley, gudanar da baki na LCZ696 ya haifar da hauhawar dogaro da kashi a cikin rigakafi na peptide na atrial natriuretic sakamakon hanawa neprilysin. A cikin berayen transgenic biyu masu hauhawar jini, LCZ696 ya haifar da dogaro da kashi da ci gaba a cikin matsananciyar bugun jini. Mahalarta lafiya, bazuwar, makafi biyu, binciken sarrafa wuribo ya tabbatar da cewa LCZ696 ya ba da hanawar neprilysin na lokaci guda da kuma toshewar mai karɓar AT1. LCZ696 yana da aminci kuma an jure shi sosai a cikin ɗan adam. [2] [3]

Magana:
McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin hanawa da enalapril a cikin gazawar zuciya. N Engl J Med. 2014 Satumba 11; 371 (11): 993-1004.
Gu J, Noe A, Chandra P, Al-Fayoumi S et al. Pharmacokinetics da pharmacodynamics na LCZ696, wani labari dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010 Afrilu; 50 (4): 401-14.
Langenickel TH, Dole WP. Angiotensin receptor-neprilysin hanawa tare da LCZ696: sabon tsarin kula da cututtukan zuciya, Drug Discov Today: Ther Strategies (2014)

 

Adana

Foda

-20°C

shekaru 3
 

4°C

shekaru 2
A cikin ƙarfi

-80°C

Wata 6
 

-20°C

Wata 1

Tsarin sinadaran

LCZ696 (Sacubitril + Valsartan)

CERTIFICATION

2018 GMP-2
原料药GMP证书201811 (captopril, thalidomide da dai sauransu)
GMP-na-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

INGANTACCEN KYAUTA

Gudanar da inganci1

Shawara18Ayyukan Ƙididdigar Ingancin Ingancin waɗanda suka amince4, kuma6ayyukan suna ƙarƙashin amincewa.

Gudanar da inganci2

Babban tsarin kula da ingancin ingancin ƙasa da ƙasa ya kafa tushe mai ƙarfi don siyarwa.

Gudanar da inganci3

Ingantattun kulawa yana gudana cikin duk tsawon rayuwar samfurin don tabbatar da inganci da tasirin warkewa.

Gudanar da inganci4

Mawakan da ake gudanarwa na kwararru yana tallafawa ingancin bukatun yayin aikace-aikacen da rajista.

SAMUN SARAUTA

cpf5
cpf6

Layin Packaging Bottled na Koriya Countec

cpf7
cpf8

Layin Marufi na CVC Taiwan

cpf9
cpf10

Layin Packaging Board CAM na Italiya

cpf11

Jamus Fette Compacting Machine

cpf12

Japan Viswill Tablet Detector

cf14-1

Dakin Kulawa na DCS

ABUNCI

Hadin gwiwar kasa da kasa
Hadin gwiwar kasa da kasa
Hadin kai na cikin gida
Hadin kai na cikin gida

  • Na baya:
  • Na gaba:

  • Ku rubuta sakonku anan ku aiko mana